688266 泽璟制药
已收盘 12-05 15:00:01
资讯
新帖
简况
泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%
证券之星 · 12-02
泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%
泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单
智通财经 · 11-24
泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单
泽璟制药计划寻求在香港上市
投资观察 · 11-20
泽璟制药计划寻求在香港上市
泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准
智通财经 · 11-18
泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准
泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌
美股速递 · 11-16
泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌
泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定
智通财经 · 11-16
泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定
泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市
智通财经 · 11-14
泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市
泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准
智通财经 · 11-13
泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准
【机构调研记录】红塔红土调研泽璟制药
证券之星 · 11-11
【机构调研记录】红塔红土调研泽璟制药
【机构调研记录】格林基金调研泽璟制药
证券之星 · 11-11
【机构调研记录】格林基金调研泽璟制药
【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）
证券之星 · 11-11
【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）
每周股票复盘：泽璟制药（688266）股价涨幅达15%登龙虎榜
证券之星 · 11-02
每周股票复盘：泽璟制药（688266）股价涨幅达15%登龙虎榜
泽璟制药（688266）2025年三季报简析：营收上升亏损收窄
证券之星 · 11-01
泽璟制药（688266）2025年三季报简析：营收上升亏损收窄
10月31日泽璟制药（688266）龙虎榜数据：机构净买入2.07亿元，北向资金净买入3854.37万元
证券之星 · 10-31
10月31日泽璟制药（688266）龙虎榜数据：机构净买入2.07亿元，北向资金净买入3854.37万元
图解泽璟制药三季报：第三季度单季净利润同比增长34.29%
证券之星 · 10-30
图解泽璟制药三季报：第三季度单季净利润同比增长34.29%
股市必读：泽璟制药（688266）10月29日收盘跌12.97%，主力净流出1.14亿元
证券之星 · 10-30
股市必读：泽璟制药（688266）10月29日收盘跌12.97%，主力净流出1.14亿元
每周股票复盘：泽璟制药（688266）ZG006为全球首个DLL3三特异性抗体
证券之星 · 10-26
每周股票复盘：泽璟制药（688266）ZG006为全球首个DLL3三特异性抗体
泽璟制药（688266）披露ZG006和ZG005在2025年欧洲肿瘤内科学会年会发布临床数据及最新进展，10月20日股价上涨1.44%
证券之星 · 10-20
泽璟制药（688266）披露ZG006和ZG005在2025年欧洲肿瘤内科学会年会发布临床数据及最新进展，10月20日股价上涨1.44%
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗活动性强直性脊柱炎的III期临床试验达到主要疗效终点
智通财经 · 10-20
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗活动性强直性脊柱炎的III期临床试验达到主要疗效终点
泽璟制药：ZG006和ZG005在2025年欧洲肿瘤内科学会（ESMO）年会发布临床数据
证券之星 · 10-19
泽璟制药：ZG006和ZG005在2025年欧洲肿瘤内科学会（ESMO）年会发布临床数据
暂无数据
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药","latestPrice":110.34,"timestamp":1764918001000,"preClose":111.32,"halted":0,"volume":1404945,"delay":0,"changeRate":-0.0088,"floatShares":265000000,"shares":265000000,"eps":-0.5038,"marketStatus":"已收盘","change":-0.98,"latestTime":"12-05 15:00:01","open":112.43,"high":112.43,"low":107.55,"amount":153000000,"amplitude":0.0438,"askPrice":110.34,"askSize":6,"bidPrice":110.27,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.5038,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":111.32,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":122.45,"lowLimit":100.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":25.42,"roa":"--","roe":"--","epsLYR":-0.52,"committee":0.424658,"marketValue":29208000000,"turnoverRate":0.0053,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-08。","afterMarket":{"amount":0,"volume":0,"close":110.34,"buyVolume":0,"sellVolume":0,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":111.32},"floatMarketCap":29208000000},"requestUrl":"/m/hq/s/688266/tweets","defaultTab":"tweets","newsList":[{"id":"2588059052","title":"泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059052?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:27","pubTimestamp":1764685649,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，泽璟制药报收于106.96元，较前一交易日下跌1.7%，最新总市值为283.13亿元。根据近日发布的《泽璟制药2025年第一次临时股东会会议资料》，苏州泽璟生物制药股份有限公司拟发行H股股票并在香港联合交易所主板上市，发行规模不超过发行后总股本的25%，募集资金将用于新药研发、产能扩张及补充流动资金。公司拟转为境外募集股份有限公司，并授权董事会全权处理上市相关事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266","HEXmain"],"gpt_icon":0},{"id":"2585468717","title":"泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468717","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468717?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:00","pubTimestamp":1763978457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司在研产品注射用ZG006被国家药品监督管理局药品审评中心(CDE)纳入突破性治疗品种公示名单，适应症为ZG006单药治疗既往至少经含铂方案治疗后复发或进展的DLL3阳性的晚期神经内分泌癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"1124974287","title":"泽璟制药计划寻求在香港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1124974287","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124974287?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:49","pubTimestamp":1763574556,"startTime":"0","endTime":"0","summary":"11月14日 - 泽璟制药（Suzhou Zelgen Biopharmaceuticals Co Ltd，股票代码：688266.SS）宣布，计划寻求在香港上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2584984363","title":"泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584984363","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584984363?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:50","pubTimestamp":1763452203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗联合用于小细胞肺癌的临床试验获得批准。ZG006 是一种针对两个不同 DLL3 表位及CD3的三特异性T细胞衔接器。临床前研究结果显示，ZG006在小鼠肿瘤模型上具有显著的肿瘤抑制作用，可以导致显著比例的小鼠肿瘤完全消退，说明ZG006 具有强效的肿瘤杀伤作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","PD","LU1169590202.USD","LU1169589451.USD","BK4023","BK0239"],"gpt_icon":0},{"id":"1172426615","title":"泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1172426615","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172426615?lang=zh_cn&edition=full","pubTime":"2025-11-16 16:04","pubTimestamp":1763280251,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，其Zg006注射剂已获得美国食品药品监督管理局（FDA）授予的孤儿药认定，用于治疗神经内分泌癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2583666507","title":"泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666507","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583666507?lang=zh_cn&edition=full","pubTime":"2025-11-16 15:50","pubTimestamp":1763279423,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)公告，公司在研产品注射用ZG006获得美国食品药品监督管理局(“FDA”)颁发孤儿药资格认定，用于治疗神经内分泌癌。公告提示，本次获得孤儿药资格认定后，公司仍需就注射用ZG006用于治疗神经内分泌癌的后续临床试验、注册申报方案等与FDA进行沟通与协商，最终能否成功完成临床试验、获得FDA上市许可及上市时间均具有不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2583457181","title":"泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583457181","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583457181?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:35","pubTimestamp":1763112927,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，为满足公司国际化战略及海外业务布局需要，提升公司国际品牌知名度，增强公司综合竞争力，公司拟发行境外上市股份(H股)并申请在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2583550238","title":"泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550238","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583550238?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:22","pubTimestamp":1763025729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006与依托泊苷及顺铂联合用于晚期神经内分泌癌的临床试验获得批准。ZG006 是一种针对两个不同 DLL3 表位及CD3的三特异性T细胞衔接器。临床前研究结果显示，ZG006在小鼠肿瘤模型上具有显著的肿瘤抑制作用，可以导致显著比例的小鼠肿瘤完全消退，说明ZG006 具有强效的肿瘤杀伤作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2582781381","title":"【机构调研记录】红塔红土调研泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582781381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582781381?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:06","pubTimestamp":1762819585,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，红塔红土近期对1家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为2.05，近一年增长56.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2582089381","title":"【机构调研记录】格林基金调研泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582089381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582089381?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:06","pubTimestamp":1762819566,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，格林基金近期对1家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。ZGGS34获中美临床批准。格林基金成立于2016年，截至目前，资产管理规模234.14亿元，排名119/211；资产管理规模228.4亿元，排名99/211；管理公募基金数61只，排名95/211；旗下公募基金经理11人，排名104/211。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2582538121","title":"【机构调研记录】华宝基金调研泽璟制药、百济神州等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2582538121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582538121?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:05","pubTimestamp":1762819525,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，华宝基金近期对3家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。ZGGS34获中美临床批准。研发费用为30,277.87万元，保持平稳。CDK4抑制剂聚焦一线乳腺癌研究，推迟披露二线数据。3）苏大维格 调研纪要：常州维普主营光掩模和晶圆缺陷检测设备，属半导体量检测核心设备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1770034418.SGD","BK1583","BK1500","LU1719994722.HKD","688235","LU2328871848.SGD","BK1161","LU0307460666.USD","BK1588","LU1251922891.USD","LU1969619763.USD","688266","LU1303224171.USD","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2580632474","title":"每周股票复盘：泽璟制药（688266）股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2580632474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580632474?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:53","pubTimestamp":1762033993,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，泽璟制药报收于103.88元，较上周的101.8元上涨2.04%。本周，泽璟制药10月31日盘中最高价报105.48元。本周关注点交易信息汇总：泽璟制药因日收盘价涨幅达15%登上龙虎榜。股本股东变化股东户数变动近日泽璟制药披露，截至2025年9月30日公司股东户数为8809.0户，较6月30日增加14.0户，增幅为0.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2580417320","title":"泽璟制药（688266）2025年三季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2580417320","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580417320?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:49","pubTimestamp":1761950985,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2025年三季报。根据财报显示，泽璟制药营收上升亏损收窄。截至本报告期末，公司营业总收入5.93亿元，同比上升54.49%，归母净利润-9341.62万元，同比上升4.58%。本次财报公布的各项数据指标表现一般。持有泽璟制药最多的基金为工银前沿医疗股票A，目前规模为96.36亿元，最新净值3.377，较上一交易日上涨5.3%，近一年上涨17.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266"],"gpt_icon":0},{"id":"2579454597","title":"10月31日泽璟制药（688266）龙虎榜数据：机构净买入2.07亿元，北向资金净买入3854.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454597","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579454597?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:48","pubTimestamp":1761904093,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年10月31日公布的交易公开信息显示，泽璟制药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年10月31日收盘，泽璟制药报收于103.88元，上涨16.14%，换手率3.52%，成交量9.33万手，成交额9.24亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入2.07亿元，北向资金合计净买入3854.37万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100037749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2579114193","title":"图解泽璟制药三季报：第三季度单季净利润同比增长34.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579114193","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579114193?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:24","pubTimestamp":1761827079,"startTime":"0","endTime":"0","summary":"证券之星消息，泽璟制药2025年三季报显示，前三季度公司主营收入5.93亿元，同比上升54.49%；归母净利润-9341.62万元，同比上升4.58%；扣非净利润-1.21亿元，同比下降15.42%；其中2025年第三季度，公司单季度主营收入2.18亿元，同比上升51.85%；单季度归母净利润-2061.26万元，同比上升34.29%；单季度扣非净利润-1803.75万元，同比上升43.96%；负债率61.87%，投资收益20.2万元，财务费用-2490.36万元，毛利率90.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266"],"gpt_icon":0},{"id":"2579189174","title":"股市必读：泽璟制药（688266）10月29日收盘跌12.97%，主力净流出1.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579189174","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579189174?lang=zh_cn&edition=full","pubTime":"2025-10-30 00:59","pubTimestamp":1761757150,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，泽璟制药报收于87.0元，下跌12.97%，换手率4.08%，成交量10.79万手，成交额9.72亿元。来自交易信息汇总：该股已连续2日下跌，前10个交易日主力资金累计净流出1.95亿元，股价累计下跌10.22%。来自交易信息汇总：近90天内11家机构对泽璟制药给出评级，其中买入评级10家，目标均价为118.11元。交易信息汇总股价提醒10月29日泽璟制药收盘报87元，跌12.97%，当日成交1079.36万元。该股已连续2日下跌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000001580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2578050025","title":"每周股票复盘：泽璟制药（688266）ZG006为全球首个DLL3三特异性抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=2578050025","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578050025?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:46","pubTimestamp":1761425169,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，泽璟制药报收于101.8元，较上周的101.49元上涨0.31%。本周，泽璟制药10月22日盘中最高价报109.9元。泽璟制药当前最新总市值269.47亿元，在化学制药板块市值排名17/150，在两市A股市值排名691/5160。本周关注点公司公告汇总：ZG006为全球首个针对DLL3靶点的三特异性抗体，在晚期小细胞肺癌患者中显示突出且持久的抗肿瘤疗效。ZG005为抗PD-1/TIGIT双特异性抗体，联合化疗在一线晚期神经内分泌癌患者中表现出良好耐受性和初步疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2576535832","title":"泽璟制药（688266）披露ZG006和ZG005在2025年欧洲肿瘤内科学会年会发布临床数据及最新进展，10月20日股价上涨1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576535832","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576535832?lang=zh_cn&edition=full","pubTime":"2025-10-20 17:14","pubTimestamp":1760951670,"startTime":"0","endTime":"0","summary":"截至2025年10月20日收盘，泽璟制药报收于102.95元，较前一交易日上涨1.44%，最新总市值为272.52亿元。公司近日发布公告称，其自主研发的新药Alveltamig和Nilvanstomig的临床研究数据及最新进展将在2025年欧洲肿瘤内科学会年会上发布。公告显示，ZG006为全球首个针对DLL3靶点的三特异性抗体，在晚期小细胞肺癌和神经内分泌癌患者中显示出突出且持久的抗肿瘤疗效，安全性良好。ZG005为抗PD-1/TIGIT双特异性抗体，联合化疗在一线晚期神经内分泌癌患者中表现出良好耐受性和初步疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000021778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2576831888","title":"泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗活动性强直性脊柱炎的III期临床试验达到主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2576831888","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576831888?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:32","pubTimestamp":1760949157,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，公司自主研发的1类新药盐酸吉卡昔替尼片(曾用名：盐酸杰克替尼片)治疗活动性强直性脊柱炎的III期临床主试验《盐酸杰克替尼片治疗活动性强直性脊柱炎患者的有效性和安全性的多中心、随机、双盲、安慰剂平行对照III期临床试验》(方案编号：ZGJAK029)达到了主要疗效终点，具有统计显著性(p<0.0001)。公司将加快推进盐酸吉卡昔替尼片治疗活动性强直性脊柱炎患者适应症的上市进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK4134","BK0239","III"],"gpt_icon":0},{"id":"2576027671","title":"泽璟制药：ZG006和ZG005在2025年欧洲肿瘤内科学会（ESMO）年会发布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2576027671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576027671?lang=zh_cn&edition=full","pubTime":"2025-10-19 15:59","pubTimestamp":1760860785,"startTime":"0","endTime":"0","summary":"泽璟制药公告称，公司自主研发的新药Alveltamig和Nilvanstomig的临床研究数据及最新进展将于2025年10月17日至21日召开的欧洲肿瘤内科学会年会上发布。ZG006是全球第一个针对DLL3靶点的三特异性抗体，是全球同类首创分子形式，具有成为同类最佳分子的潜力。ZG005是全球率先进入临床研究的同靶点药物之一，目前全球范围内尚未有同类机制药物获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900002592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764968995538,"stockEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":0.085},{"period":"3month","weight":-0.0869},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.6575},{"period":"ytd","weight":0.7708}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8809人(较上一季度增加0.16%)","perCapita":"30049股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药,688266,泽璟制药股票,泽璟制药股票老虎,泽璟制药股票老虎国际,泽璟制药行情,泽璟制药股票行情,泽璟制药股价,泽璟制药股市,泽璟制药股票价格,泽璟制药股票交易,泽璟制药股票购买,泽璟制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}